Shanghai RAAS completes Nanyue Biopharma acquisition

Shanghai RAAS Blood Products (SZSE:002252) announced the completion of its acquisition of Nanyue Biopharmaceutical Co., Ltd., solidifying its 100% equity stake. The transaction, initially detailed in a March 27, 2025 announcement, involved acquiring shares from multiple parties, including individual shareholders and investment partnerships. The base consideration for 100% of Nanyue Biopharmaceutical was CNY 4.2 billion. An additional contingent payment of CNY 50 million is payable to the original controlling shareholder, Liu Lingan, if Nanyue Biopharmaceutical achieves a plasma collection volume of 305 tons in 2025. Following the completion of the acquisition and related registration procedures, Nanyue Biopharmaceutical becomes a wholly-owned subsidiary of Shanghai RAAS. The company intends to actively promote the daily operations and key projects of Nanyue Biopharmaceutical.